Barrington Research has acted as Co-Manager in a $10 Million underwritten public offering of common stock for LeMaitre Vascular, Inc. (LMAT).

Barrington Research has acted as Co-Manager in a $10 Million underwritten public offering of common stock for LeMaitre Vascular, Inc. (LMAT).

Barrington Research has acted as Co-Manager in a $10 Million underwritten public offering of common stock for LeMaitre Vascular, Inc. (LMAT).

$10,010,000

Common Stock Public Offering Co-Manager

June 2014

CHICAGO, June 5, 2014 — Barrington Research Associates, Inc. (www.brai.com), a nationally recognized investment services firm, has acted as Co-Manager in a $10 Million underwritten public offering of common stock for LeMaitre Vascular, Inc. (LMAT).

The offering consisted of 1,430,000 shares of its common stock offered to the public priced at $7.00 per share and includes an overallotment option up to an additional 214,500 shares of common stock. The transaction closed on June 4, 2014.

Canaccord Genuity and Stifel acted as joint book-running managers in the offering. Co-Manager’s included Barrington Research Associates, The Benchmark Company, Brean Capital, and Roth Capital Partners.
The offering was made pursuant to a shelf registration statement (File No. 333-195658) previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Any offer, solicitation or sale will be made only by means of the prospectus supplement and the base prospectus.

About LeMaitre Vascular

LeMaitre Vascular is a provider of devices for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.